Home Newsfeeds Morgan Stanley Upgrades Stride to Overweight, Announces $45 Price Target

Morgan Stanley Upgrades Stride to Overweight, Announces $45 Price Target

Morgan Stanley analyst Greg Parrish upgrades Stride (NYSE:LRN) from Equal-Weight to Overweight and announces $45 price target.

byBenzinga Newsdesk

August 25, 2022

1 minute read

Morgan Stanley analyst Greg Parrish upgrades Stride (NYSE:LRN) from Equal-Weight to Overweight and announces $45 price target.

Ryan Cohen Takes Stake In Alibaba — Nudges Board To Boost Share Buybacks By Another $20B: WSJ

By Bhavik Nair

January 16, 9:18 PM

Activist investor Ryan Cohen has reportedly acquired a stake in Chinese e-commerce giant Alibaba Group Holding Ltd. (NYSE:

AAPL

Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday’s Pre-Market Session

By Avi Kapoor

January 16, 6:53 AM

U.S. stock futures were lower this morning, with the Nasdaq futures falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s pre-market trading session.

APLD

George Soros’ Investment Firm Has $500M Stake In Broad Market ETF

By Ryan Gustafson

November 14, 7:40 PM

Soros Fund Management released its 13F filing for the third quarter of 2023 on Tuesday evening, with $7,046,620,776 reported in managed 13F securities. Soros Fund Management's largest holding was in

QQQ

Nature Medicine Publishes Results From Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE Efficacy And Safety In Patients With Rett Syndrome

By Happy Mohamed

June 8, 11:14 AM

-- Statistically significant differences demonstrated between DAYBUE™ and placebo on efficacy endpoints relevant to Rett syndrome suggest treatment potentially capable of modifying core symptoms consistent

ACAD

Morgan Stanley Upgrades Stride to Overweight, Announces $45 Price Target

Related Posts

Ryan Cohen Takes Stake In Alibaba — Nudges Board To Boost Share Buybacks By Another $20B: WSJ

Applied Digital, ESSA Pharma And Other Big Stocks Moving Higher In Tuesday’s Pre-Market Session

George Soros’ Investment Firm Has $500M Stake In Broad Market ETF

Nature Medicine Publishes Results From Pivotal Phase 3 LAVENDER Study Evaluating DAYBUE Efficacy And Safety In Patients With Rett Syndrome